Holen Sie sich die Stockscreener-App
122.13
4.36%
-5.57
Schlusskurs vom Vortag:
$127.70
Offen:
$126.78
24-Stunden-Volumen:
539.01K
Relative Volume:
0.55
Marktkapitalisierung:
$7.45B
Einnahmen:
$521.31M
Nettoeinkommen (Verlust:
$-23.36M
KGV:
-255.45
EPS:
-0.4781
Netto-Cashflow:
$54.87M
1W Leistung:
-2.75%
1M Leistung:
+29.93%
6M Leistung:
+41.08%
1J Leistung:
+130.39%
1-Tages-Spanne:
$118.54
$127.51
1-Wochen-Bereich:
$118.11
$130.00
52-Wochen-Spanne:
$50.25
$130.00
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
Firmenname
Mirum Pharmaceuticals Inc
Sektor
Branche
Telefon
650-667-4085
Adresse
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Compare MIRM vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
122.13 | 7.45B | 521.31M | -23.36M | 54.87M | -0.4781 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-18 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-09-24 | Eingeleitet | TD Cowen | Buy |
| 2025-08-11 | Fortgesetzt | Stifel | Buy |
| 2025-05-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-04-17 | Eingeleitet | Stifel | Buy |
| 2023-12-18 | Bestätigt | H.C. Wainwright | Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-11-13 | Eingeleitet | Morgan Stanley | Overweight |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-17 | Fortgesetzt | Evercore ISI | Outperform |
| 2023-09-20 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-09-01 | Eingeleitet | Citigroup | Buy |
| 2021-09-20 | Eingeleitet | JP Morgan | Overweight |
| 2020-08-07 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2020-08-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-07-31 | Eingeleitet | Piper Sandler | Overweight |
| 2020-06-25 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-08-12 | Eingeleitet | Citigroup | Buy |
| 2019-08-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-08-12 | Eingeleitet | Guggenheim | Buy |
| 2019-08-12 | Eingeleitet | ROTH Capital | Buy |
| 2019-08-12 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Mirum Pharmaceuticals Inc Aktie (MIRM) Neueste Nachrichten
MIRM Stock Clocks Best Day In 4.5 Months On Liver Disease Trial Data: Retail Eyes Buyout At A Premium - Stocktwits
Why is Mirum Pharmaceuticals (MIRM) down 10.1% since last earnings report? - MSN
Insider Sell Alert: Eric Bjerkholt Sells 5,000 Shares of Mirum P - GuruFocus
Form 4 Mirum Pharmaceuticals Inc For: 8 July By Investing.com - Investing.com Nigeria
Mirum Pharmaceuticals Insider Sold Shares Worth $611,273, According to a Recent SEC Filing - Moomoo
Mirum Pharmaceuticals Insider Sold Shares Worth $2,445,382, According to a Recent SEC Filing - Moomoo
Mirum Pharmaceuticals CEO Christopher Peetz sells $2.4 million in stock - Investing.com
Mirum Pharmaceuticals CFO Eric Bjerkhot sells $611,273 in stock - Investing.com
Mirum Pharmaceuticals CFO Eric Bjerkhot sells $611,273 in stock By Investing.com - Investing.com India
Mirum Pharmaceuticals CEO Christopher Peetz sells $2.4 million in stock By Investing.com - Investing.com India
Mirum Pharmaceuticals (MIRM) CEO sells 20,000 shares after exercising options - Stock Titan
Mirum Pharmaceuticals (MIRM) CFO sells 5,000 shares under 10b5-1 plan - Stock Titan
Why (MIRM) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Mirum Pharmaceuticals outlines its liver disease focus as shares trade on Nasdaq - AD HOC NEWS
RBC Capital Adjusts Mirum Pharmaceuticals Price Target to $148 From $142, Maintains Outperform Rating - marketscreener.com
Christopher Peetz plans 20,000-share sale (NASDAQ: MIRM) - Stock Titan
Eric Bjerkholt reports sale of 5,000 MIRM shares (MIRM) - Stock Titan
Enterprise value to EBIT forward of Mirum Pharmaceuticals, Inc. – NASDAQ:MIRM - TradingView
Mirum Pharmaceuticals: This Liver Disease Juggernaut Just Broadened Its Portfolio - Seeking Alpha
MIRMMirum Pharmaceuticals Inc Latest SEC Filings - Finviz
Insider Sell: Jolanda Howe Sells Shares of Mirum Pharmaceuticals Inc (MIRM) - GuruFocus
Mirum Pharmaceuticals SVP sells $326,520 in common stock By Investing.com - Investing.com South Africa
Form 4 Mirum Pharmaceuticals Inc For: 2 July By Investing.com - Investing.com Canada
Mirum Pharmaceuticals SVP sells $326,520 in common stock - Investing.com
Mirum Pharmaceuticals (MIRM) SVP Howe sells 2,721 shares under 10b5-1 plan - Stock Titan
Mirum Pharmaceuticals stock hits all-time high at 125.41 USD By Investing.com - Investing.com South Africa
Mirum Pharmaceuticals stock hits all-time high at 125.41 USD - Investing.com
J.P. Morgan Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Raises Target Price to $125 - Moomoo
The Bull Case For Mirum Pharmaceuticals (MIRM) Could Change Following Priority FDA Review Of FOP Drug Zilurgisertib - Yahoo Finance
Form 144 MIRUM PHARMACEUTICALS For: 1 July By Investing.com - Investing.com Canada
2,721 performance shares proposed; Jolanda Howe sold 2,594 (MIRM) - Stock Titan
Mirum Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Fischer Laurent - Moomoo
Strength Seen in Mirum Pharmaceuticals (MIRM): Can Its 5.5% Jump Turn into More Strength? - Yahoo Finance
5 Biotech Stocks That Skyrocketed 105% To 235% — TWST, INDV, MIRM & More - RTTNews
Mirum Pharmaceuticals Stock Surges 25%, With A 9-Day Winning Spree - Trefis
Enterprise value to EBITDA forward of Mirum Pharmaceuticals, Inc. – NASDAQ:MIRM - TradingView
Price to book forward of Mirum Pharmaceuticals, Inc. – NASDAQ:MIRM - TradingView
Mirum and Incyte's zilurgisertib shows positive phase 2 data in FOP - MSN
Enterprise value to revenue forward of Mirum Pharmaceuticals, Inc. – NASDAQ:MIRM - TradingView
Price to sales forward of Mirum Pharmaceuticals, Inc. – NASDAQ:MIRM - TradingView
Price to earnings forward of Mirum Pharmaceuticals, Inc. – NASDAQ:MIRM - TradingView
Understanding Momentum Shifts in (MIRM) - Stock Traders Daily
Price to earnings forward of Mirum Pharmaceuticals, Inc. – HAM:08D - TradingView
9-Day Rally Sends Mirum Pharmaceuticals Stock Up 25% - Trefis
MIRM, INCY report positive rare disease data as FDA begins NDA review - MSN
MIRM Forecast — Price Target — Prediction for 2027 - TradingView
Mirum Pharmaceuticals Stock Surges 18%, With A 8-Day Winning Spree - Trefis
MIRM Technical Analysis & Stock Price Forecast - Intellectia AI
Mirum Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:MIRM) - TradingView
08D Forecast — Price Target — Prediction for 2027 - TradingView
Is Mirum Pharmaceuticals, Inc. (MIRM) Emerging as a Rare Disease Growth Story After New FOP Data? - Insider Monkey
Finanzdaten der Mirum Pharmaceuticals Inc-Aktie (MIRM)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):